Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15

Benzinga · 1d ago
Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.